22nd CARDIOVASCULAR SUMMIT TCTAP 2017 April 25-27, 2017 Coex, Seoul, Korea

New Road for Carotid Intervention:

Transradial and Transcervical Access With Flow Reversal

Prof. Piotr Pieniazek MD PhD



John Paul II Hospital in Krakow, Jagiellonian University Institute of Cardiology, Krakow, Poland



Potential conflicts of interest

Piotr Pieniazek, MD, Ph.D.

1 have the following potential conflict of interests to be reported. Consulting; Study Honoraria; Travel Expenses; Trials Involvement: **Boston Scientific** □Terumo _Balton ■Astra Zeneca

Target ICA access anatomy:

can be crucial in determining CAS feasibility & safety

⇒ less contrast use / less time / less risk when access anatomy is defined prior to CAS!



Access Site Complications: Most technical failures are related to complex arch !!!



Cannulation difficulties of CCA during CAS

Final Consideration: Physician training requirements



Addressing shellonges			CAS experience (no.)			
	Addressing challenges			100-200	>200	
	Aortic arch:	Ш	No	No	Yes	
	Lesion anatomy:	angled	No	Yes	Yes	
	Vessel anatomy:	severely tortuous	No	No	Yes	
	Lesion characteristics:	angled, severely calcified, high grade, sub-occlusive	No	Yes	Yes	
	Plaque composition:	dis-homogeneous, soft, ulcerated	No	Yes	Yes	





Why Do We Need to Develop CAS via Radial Access ????

Femoral Approach Limitations !!!

Aortoiliac disease or occlusion (Lerishe's Syndrom)

Previous surgical bypass of peripheral arteries

Severe aortic arch angulation incl. bovine arch

History of stent graft implantation

Significant overweight

Large hernia

Spine disease causing intolerance of lying after CAS

Hematological disease or warfarin therapy

Unique solution for transradial access interventions!! Glidesheath SLENDER !

TERUMO"	For Radial Access	Boston	
	Glidesheath Slender Fr. 7	Scientine (7)	
17)1717	RM*RS7F10PQ	Guider Softip™ XF	
735072		40 XF Guide Cetheter, Center pile, Centerr pide, Rehnungskatheter, Lander Detheter, Center pile, Centerr pide, Rehnungskatheter, Lander Cetheter, Center pile, Centerr pide, Rehnungskatheter,	A CONTRACT OF
3000		Canner pick, Veriferen pick, Stylaster, Vezetikazen, Caner Kateler Odnyk szlistépek, Caner pick, Stylaster, 2005 开始时, Kilandz Kateler Cennik provativer, Ludukater, 309号星, 2005 开始时, Kilandz Kateler	
NU		100cm	and the second of the second of the
=	Image: 10cm		
0	C 2. 45mm (MIN 2. 33mm) C 2/5"(35mm)	0.073in (1 Simm) Dade Labore Samere	
Destricate Survey	150710 3 2017-12	10143	R ALLANS
	A) In the second secon	REF 2017-10	1 1 1 0

Save radial and ulnar artery for the next intervention

Special devices are crucial for radial access CAS



Specially dedicated diagnostic cath.(Cobra 1&2&3 5F.), DuraGlide Jindo or Glidewire Advantage, Independent Filter (Spider RX or Wirion)

Roadsaver - the most flexible carotid stent on market



Restenosis 6 Months After Surgical Carotid Endarterectomy Pt. selected for CEA due to difficult access to LCCA from femoral approach



Bovine arch - one of the main indications for radial approach to CAS

Multilevel restenosis after CEA requiring stent with high radial force



Most important in radial technique is stent and retrieval device delivery Corotid Wallstent and WIRION filter have been used Case # 3286!! 62 y.o. patient after neck surgery and radiation with severe PAD. Symptomatic RICA lesion !! CAS from radial access was the only option !!!!



62 y.o. patient after neck surgery and radiation with severe PAD Symptomatic RICA lesion! CAS from radial access was the only option!!!

Case # 3286!! 62 y.o. patient after neck surgery and radiation with severe PAD. Symptomatic RICA lesion !! CAS from radial access was the only option !!!!



Cobra diagnostic cath, Advantage 0.035", Guider Softip XF and SPIDER FX our routine practice. (predilatation – optional) RoadSaver stent is no. 1 indication in this particular situation. Some aggressive postdilatation.

Case # 3286!! 62 y.o. patient after neck surgery and radiation with severe PAD. Symptomatic RICA lesion !! CAS from radial access was the only option !!!!



Right haemisphere before CAS

Final angio !!

Right haemisphere after CAS

Advantages of CAS from radial access:

Importance of early ambulations

- Patient's comfort and satisfaction
- Reducing nursing cost
- **Reducing vagal reaction**
- Reducing hypotensive response
- Reducing bleeding complication



Vascular surgeon

77.23

Vascular surgeon

ALL AL ANEL LY ME

Cardiologist

Introducing TCAR TransCarotid Artery Revascularization The Clinically Proven, Less Invasive Alternative to CEA

Combines direct carotid access with robust flow reversal during Transcarotid stent placement Why do we need new access for carotid stenting e.g Direct common carotid access.

No femoral (Lerishe's syndrom) or radial access (many PCI intervention)

We need proximal protection in high risk patients with no femoral access

CAS done by vascular surgeons can be more save with direct access than with endovascular technique.

TCAR is promising technique for high risk patient with difficult femoral and radial access.

Carotid Revascularization Options

Gold Standard Carotid Endarterectomy

- Low stroke risk¹, but...
- Invasive; risk of surgical complications
 - Risk of cranial nerve injury²
 - MI rates 2X that of TF-CAS¹



CREST CNI Rates: 2.1% CNI unresolved at 6 months (80% motor) CREST MI Rates: 2.3% CEA vs 1.1% TF CAS

Less Invasive Alternative Transfemoral, Filter Protected CAS CAS

- Patient friendly, long-term durability¹, **but...**
- Excess procedural stroke risk¹
 - Unprotected arch and disease navigation; lower embolic capture rate from misaligned filters



CREST 30-day All Stroke Rates: 2.3% CEA vs 4.1% TF CAS

¹CREST Trial: N Engl J Med 2010;363:11-23 ² Circulation. 2012;125:2256-2264

TCAR – A Surgically Inspired Less Invasive Alternative to CEA

Direct Carotid Access CCA Clamp & Loop Control





Back-bleeding to Clear Debris



Direct Carotid Access (avoid arch) CCA Clamp & Loop Control





TCAR

Flow Reversal to Clear Debris TCAR Procedure Transcarotid Artery Revascularization

Oirect Carotid Acces



First-in-Poland John Paul II Hospital direct carotid access CAS (TCAR) Under En Route (SilkRoad Medical) Flow Reversal

Courtesy : P Musialek



movie

movie

Courtesy; P Musialek



lesion crossing, predil, CGuard stent implantation and postdil under En Route (SilkRoad Medical) Flow Reversal

Courtesv :P Musialek



full endovascular reconstruction

First-in-Poland direct carotid access CAS under En Route (SilkRoad Medical) Flow Reversal

Courtesy:P Musialek



Guard 7.0x30mm full endovascular reconstruction *First-in-Poland* direct carotid access CAS under En Route (SilkRoad Medical) Flow Reversal Courtesy: P Musialek J Vasc Surg. 2015 Nov;62(5):1227-34. doi: 10.1016/j.jvs.2015.04.460.

Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal.

Kwolek CJ¹, Jaff MR², Leal JI³, Hopkins LN⁴, Shah RM⁵, Hanover TM⁶, Macdonald S⁷, Cambria RP⁸.

Author information

Abstract

OBJECTIVE: This report presents the 30-day results of the Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure (ROADSTER) multicenter trial and evaluates the safety and efficacy of ENROUTE Transcarotid NPS (Silk Road Medical Inc, Sunnyvale, Calif), a novel transcarotid neuroprotection system that provides direct surgical common carotid access and cerebral embolic protection via high-rate flow reversal during carotid artery stenting (CAS).

METHODS: A prospective, single-arm, multicenter clinical trial was performed to evaluate the use of the ENROUTE Transcarotid NPS during CAS procedures performed in patients considered to be at high risk for complications from carotid endarterectomy. Symptomatic patients with ≥50% stenosis and asymptomatic patients with ≥70% stenosis were eligible to be treated with any U.S. Food and Drug Administration-approved carotid artery stent. The primary end point was the composite of all stroke, myocardial infarction (MI), and death at 30 days postprocedure as defined in the Food and Drug Administration-approved study protocol. Secondary end points included cranial nerve injury; 30-day stroke, death, stroke/death, and MI; acute device, technical, and procedural success; and access site complications. All major adverse events were adjudicated by an independent clinical events committee.

RESULTS: Between November 2012 and July 2014, 208 patients were enrolled at 18 sites. Sixty-seven patients were enrolled as lead-in cases, and 141 were enrolled in the pivotal phase. In the pivotal cohort, 26% were symptomatic and 75% were asymptomatic. Acute device and technical success were 99% (140 of 141). By hierarchical analysis, the all-stroke rate in the pivotal group was 1.4% (2 of 141), stroke and death was 2.8% (4 of 141), and stroke, death and MI was 3.5% (5 of 141). One patient (0.7%) experienced postoperative hoarseness from potential Xth cranial nerve injury, which completely resolved at the 6-month follow-up visit.

CONCLUSIONS: The results of the ROADSTER trial demonstrate that the use of the ENROUTE Transcarotid NPS is safe and effective at preventing stroke during CAS. The overall stroke rate of 1.4% is the lowest reported to date for any prospective, multicenter clinical trial of CAS.

TRIAL REGISTRATION: ClinicalTrials.gov NCT01685567.

TCAR - Clinically proven less invasive alternative to CEA

Clinically Proven, Surgically Inspired *Neuroprotection* Low 1.4% 30-day all stroke rate

- Direct carotid access with CCA clamp & vessel control
- Robust flow reversal akin to CEA backbleeding

Less Invasive, Patient-Friendly Procedure
Reduced rates of MI & cranial nerve injury
Cosmetic result of a less invasive procedure

Local anesthesia can improve recovery time

ROADSTER 2 Post-Approval Study is Currently Enrolling

Conclusion:

Carotid artery stenting with EPD can be perform safely and effectively using radial access

In severe PAD or difficult aortic arch anatomy transradial CAS can be more save then transfemoral access.

Thanks to New generation of DC, GC, Sheaths, GW, Filters and Stents CAS procedure is fast and safe.

TCAR is a new and very promising therapeutic option for CAS

All centers performing CAS should know the radial access technique and VS should start to use EnRoute(Silkroad Medical) device in particular patients

